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Abstract There is a lack of knowledge on the epidemiology
of fungal infections worldwide because there are no reporting
obligations. The aim of this study was to estimate the burden
of fungal disease in Portugal as part of a global fungal burden
project. Most published epidemiology papers reporting fungal
infection rates from Portugal were identified. Where no data
existed, specific populations at risk and fungal infection fre-
quencies in those populations were used in order to estimate
national incidence or prevalence, depending on the condition.
An estimated 1,510,391 persons develop a skin or nail fungal
infection each year. The second most common fungal infec-
tion in Portugal is recurrent vulvovaginal candidiasis, with an
estimated 150,700 women (15–50 years of age) suffering
from it every year. In human immunodeficiency virus
(HIV)-infected people, oral or oesophageal candidiasis rates
were estimated to be 19.5 and 16.8/100,000, respectively.
Candidaemia affects 2.19/100,000 patients, in a total of 231
cases nationally. Invasive aspergillosis is less common than in
other countries as chronic obstructive pulmonary disease
(COPD) is uncommon in Portugal, a total of 240 cases annu-
ally. The estimated prevalence of chronic pulmonary
aspergillosis after tuberculosis (TB) is 194 cases, whereas its
prevalence for all underlying pulmonary conditions was 776
patients. Asthma is common (10% in adults) and we estimate
16,614 and 12,600 people with severe asthma with fungal
sensitisation and allergic bronchopulmonary aspergillosis, re-
spectively. Sixty-five patients develop Pneumocystis pneumo-
nia in acquired immune deficiency syndrome (AIDS) and 13
develop cryptococcosis. Overall, we estimate a total number
of 1,695,514 fungal infections starting each year in Portugal.
Introduction
Despite their growing importance, many fungal infections
have been neglected all over the world until recently. More
fungal diseases than ever before are now being encountered in
a wider range of human hosts and caused by a large array of
fungal species. Prevalence depends on many factors, such as
the number of persons with underlying diseases associated
with an increased risk for fungal infection, invasive proce-
dures and antifungal therapies used. The prevalence of such
infections thus varies greatly across different countries, and it
is, therefore, mandatory to estimate the actual fungal burden in
each country, in order to fully grasp the current scenario of
these emergent infections.
Portugal is geographically situated on the west coast of
Europe and includes the archipelagos of the Azores and
Madeira. The estimated population is over 10,500 million
people [1]. Portugal has also accepted large inflows of immi-
grants from its former colonies in Africa, from Central and
Eastern Europe and from Brazil.
According to the European Centre for Disease Prevention
and Control (ECDC) [2], Portugal is the Western European
country with comparatively higher estimates of human immu-
nodeficiency virus (HIV) and tuberculosis (TB) proportions,
In association with the LIFE program at http://www.LIFE-worldwide.org
* R. Sabino
raquel.sabino@insa.min-saude.pt; raquelsabino@hotmail.com
1 Infectious Diseases Department, National Institute of Health Dr.
Ricardo Jorge—Reference Unit for Parasitic and Fungal Infections,
Lisbon, Portugal
2 Centro Hospitalar Lisboa-Norte, EPE, Lisbon, Portugal
3 Department of Biology, Centre of Molecular and Environmental
Biology (CBMA), University of Minho, Braga, Portugal
4 The University of Manchester and National Aspergillosis Centre,
University Hospital of South Manchester, Manchester, UK
Eur J Clin Microbiol Infect Dis
DOI 10.1007/s10096-017-2930-y
having also the highest proportion of co-infected cases.
Furthermore, the incidence of cancer has also been noticeably
increasing in this country in recent years [3].
Until a few decades ago, the prevalence of fungal infections
was low or unknown in Portugal, which may be explained by
the lack of regular and national surveillance and the lack of
obligatory reporting of the occurrence of these infections. The
ones with highest prevalence were (and still are) those with
very low mortality and morbidity (e.g. dermatomycosis and
vaginal candidiasis). As yet, national statistics of the majority
of invasive infections have not been generated and the infor-
mation available is very scarce or non-existent.
As a consequence, until recently, the public health impor-
tance of mycology has been underestimated by the national
scientific community.
The aim of this work is to estimate the burden of serious
fungal disease in Portugal using deterministic scenario model-
ling and published incidence and prevalence data.
Methodology
Relevant literature was searched via PubMed and several oth-
er search tools using different sets of key words (in Portuguese
and English): ([Candidemia Portugal]; [Aspergilose Portugal];
[Infeções Fúngicas Portugal]; [Mucormicose Portugal];
[Mucormicose Portugal]; [Candidose vaginal Portugal];
[Infeções hospitalares Portugal]; [Infeções oculares
Por tuga l ] ; [ In feções fúng icas o lhos Por tuga l ] ;
[Histoplasmose Portugal]. A simple deterministic model that
was created in Excel and has consistently been applied in
many countries by the LIFE program was used [4, 5]. For
the purpose of creating a comparable dataset for each country,
a template was provided to all participants that included de-
mographic data, and specific disease-related information was
gathered. The template used across the countries involved
extrapolated estimates of fungal infection from published data.
Standardised assumptions, which allow directly observed in-
cidence of fungal infection to be used in conjunction with
surrogate markers, enabled an estimate of the total national
burden to be derived. Thus, where no data existed, specific
populations at risk were used and the frequency of fungal
infections on those populations was applied to estimate the
national incidence or prevalence, depending on the condition.
In the absence of local data, published estimates from neigh-
bour countries were used.
Population statistics were obtained from the National
Statistics Institute – Statistics Portugal [6] and demographic
data collected from the census performed in 2011 [1]. Data
regarding underlying diseases and risk factors [HIV/acquired
immune deficiency syndrome (AIDS), pulmonary tuberculo-
sis (PTB), oncological diseases, respiratory diseases and the
number of solid organ transplants] were collected from differ-
ent national and international studies [2, 3, 7–18].
The number of chronic pulmonary aspergillosis (CPA)
cases was estimated using the previously described approach
taken by Denning et al. [19] in their global estimates, where
the number of annual PTB cases with cavities (12%) was
multiplied by the incidence of CPA in cavities (22%) and the
number of PTB cases without cavities (88%) was multiplied
by CPA incidence (2%). The number of histoplasmosis epi-
sodes occurred during 2015 were obtained from the
Diagnostic Homogeneous Groups database, made available
by the Central Administration of the Health System [12].
The number of critical care beds in Portugal (data from
2013) was also obtained from the Central Administration of
the Health System [12].
Data from skin and nail infections were collected from
different local studies [20, 21].
Results and discussion
Country profile
In 2011, the Portuguese total population was estimated to be
10.6 million (Table 1), with 47.8% being males and 52.2%
being females. 14.9% of the individuals were estimated to be
below 15 years old, whereas 25.0% were estimated to be 60
years old or more. 23.8% of the population is constituted by
women aged from 15 to 49 years old [1]. In 2013, the gross
domestic product per capita was $21,733 [22]. All residents in
Portugal have access to healthcare provided by the National
Health Service, financed mainly through taxation.
Approximately one-fifth to a quarter of the population enjoys
a second (or more) layer of health insurance coverage, through
health subsystems and voluntary health insurance. Healthcare
delivery is based on both public and private providers. The
primary care system in Portugal performs well, with rates of
avoidable hospitalisation amongst the best in the Organisation
for Economic Co-operation and Development (OECD) for
asthma and chronic obstructive pulmonary disease (COPD)
Table 1 Portuguese population profile
Population data Number (%)
Population in Portugal 10,562,178 (100%)
Population over 40 years old 5,588,208 (52.9%)
Children (0–14 years old) 1,572,329 (14.8%)
Adults (≥15 years old) 8,989,849 (85.2%)
Adult women 4,747,248 (44.9%)
Women over 60 years old 1,503,935 (31.6% adult women)
Women aged 15–50 years 2,511,645 (52.9% adult women)
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[23]. The number of critical care beds in continental Portugal
was estimated as 666 [12].
Due to the scarcity of national epidemiological data, almost
every estimate was based on modelling combined with the
few epidemiology papers found.
Pneumocystis pneumonia and cryptococcosis
In the period from 1983 to 2015, the total number of fungal
infections in HIV+/AIDS patients is reported in Table 2 (data
not published: cases notified until 31 December 2015, data-
base HIV, Surveillance on HIV-AIDS infection – National
Institute of Health Dr. Ricardo Jorge) [7]. The incidence of
HIV was estimated to be 14.0 cases/100,000 inhabitants in
2013 [8]. Of the 30,956 HIV cases reported by the end of
2014, data regarding antiretroviral therapy (ART) were avail-
able for 26,580. Overall, 22,005 (82.8%) of the patients were
prescribed ART, while 4575 (17.2%) were not [8] (Table 2). In
2014, 920 new HIV cases were reported. 914 (99%) of these
cases were diagnosed in adults over 15 years old; in 51.2%,
the CD4+ count was <350 cells/mm3 and in 33.1% of cases it
was <200 cells/m3. During 2014, 249 new cases of AIDSwere
diagnosed. In 65 cases (26.2%), pneumonia caused by
Pneumocystis jirovecii (PCP) was diagnosed and 13 (5.2%)
patients were diagnosed with extrapulmonary cryptococcosis.
The annual incidence of PCP was calculated to be 0.61/
100,000 inhabitants and of extrapulmonary cryptococcosis
to be 0.12/100,000 inhabitants [8].
When compared to other similar European studies [5, 24,
25], Portugal shows the highest annual incidence of crypto-
coccal meningitis but one of the lowest incidences of
Pneumocystis pneumonia. The high number of HIV-infected
patients without antiretroviral treatment (17%) together with
the very easy diagnosis of cryptococcosis (in contrast to PCP)
may explain this apparent disparity in incidence rates.
Aspergillus infections
In 2014, the incidence of tuberculosis in Portugal was 25/
100,000 inhabitants (Table 3). During this year, 2169 TB
cases were notified and PTB was the most prevalent manifes-
tation, in 1558 cases [11]. The number of deaths attributed to
PTB was 160. Treated PTB can lead to complications, includ-
ing progressive loss of lung function, persistent pulmonary
symptoms and CPA [19] (Table 3). Therefore, and following
previous assumptions, the annual CPA incidence is estimated
to be 62 patients, with a 5-year period prevalence of 194
people with CPA following PTB [19]. Assuming that the
PTB patients represent only a quarter of CPA cases in a year
[5], and that the other three-quarters are due to COPD, sar-
coidosis, allergic bronchopulmonary aspergillosis (ABPA),
prior pneumothorax, rheumatoid arthritis and non-
tuberculosis mycobacterial infection, it is inferred that there
is a prevalence of ∼776 cases of CPA in Portugal.
The total number of cystic fibrosis (CF) cases was 320 in
2015, with 79 individuals aged more than 18 years old [26].
Only two adult CF patients are recorded as having ABPA, but
an anticipated seven have ABPA and another 11 Aspergillus
bronchitis.
It is estimated that about 10% of the Portuguese adult pop-
ulation suffers from asthma, with a total number of patients
that varies between 700,000 and 1,000,000 in 2014. We
Table 2 Portuguese human
immunodeficiency virus (HIV)-
related data
HIV-related data Patient numbers
(actual)
References
Current total HIV/AIDS 30,956 [7, 8]
Proportion of diagnosed cases on ARVs 22,005
Number of diagnosed cases not receiving ARVs 4575
Annual new AIDS cases (at risk of OIs) 249
Proportion of AIDS patients presenting with PCP 26%
Proportion of AIDS patients presenting with cryptococcal
meningitis
5%
HIV patients who died in 2014 196
AIDS-related deaths in 2011 126
Total no. of cases
(1983–2015)
Pneumocystis pneumonia 4418 [7]
Oesophageal candidiasis 1777
Cryptococcosis 1028
Tracheal/pulmonary/bronchic candidosis 32
Histoplasmosis 8
Coccidioidomycosis 4
Eur J Clin Microbiol Infect Dis
decided to choose the lowest estimate [27]. It is also estimated
that about 12.5% of Portuguese children suffer from asthma.
ABPA numbers were determined by assuming rates of 2.5%
among adult asthmatics, totalling ∼12,600 patients [26, 28].
For severe asthma with fungal sensitisation (SAFS), the as-
sumption is that, among asthmatics with the most severe dis-
ease (10% of adult asthma patients), a third will be affected
(16,614 patients) [29] (Table 3). There is likely some overlap
between ABPA and SAFS estimates depending on the propor-
tions of ABPA patients with severe asthma and SAFS patients
who are sensitised to Aspergillus. The estimated annual inci-
dence of ABPA and SAFS is lower than in other European
countries, whereas the annual incidence of CPA is higher in
our country than in Germany, Ireland and Denmark. Our esti-
mated values need to be confirmed and improved diagnostic
testing such as Aspergillus IgE and IgG testing are needed to
further validate these data and should be used routinely as
diagnosis tools [30].
A 1.1% prevalence of COPD in the Portuguese population
was estimated nationally [13]. This percentage is probably
very low due to the under-diagnosis of this disease. In fact,
Bárbara et al. [17] performed a study on the prevalence of
COPD in adults aged ≥40 years old in the Lisbon area and
found a much higher level of prevalence (14.2%). The total
number of COPD admissions to hospital per year totalled
6383, according to the OECD report [16] (Table 3). The rate
of invasive aspergillosis (IA) attributable to COPD patients
assumes that 1.3% of COPD admissions developed IA: a total
of 83 cases of COPDwill develop IA every year. According to
Yan et al. [31], 2.63% of the patients diagnosed with lung
cancer develop IA. Portugal has a high incidence of lung can-
cer and about 3500 new cases are diagnosed every year [32],
which corresponds to an estimate that 92 patients with lung
cancer will develop IA.
In a one-year study (2015) on invasive fungal infec-
tions (IFI) in haematological patients in one of the major
central hospitals of Lisbon, 17 cases of IA were diag-
nosed. Among those, eight were allogeneic stem cell
transplanted (HSCT) patients. The number of HSCT in
this hospital during 2015 was 26. These data generate an
estimate of 31% IA incidence in HSCT patients in this
hospital and we used this value to extrapolate to the total
number of 46 cases per year in our country, since we had
147 HSCT during 2015. Therefore, 65 cases of IA were
estimated annually in HSCT and solid organ-transplanted
patients, assuming that IA (proven and probable) occurred
in 6% of heart, 4% of lung and liver and 1% of kidney-
transplanted patients [33] (Table 4). The estimated IA rate
is lower than other European countries but similar to those
estimated by Spain [5] or the Czech Republic [25].
Table 3 Portuguese profile of
respiratory diseases Respiratory diseases Number References
Pulmonary tuberculosis annual incidence HIV+ 3,5/100,000 inhabitants [2, 8–10]
Pulmonary tuberculosis annual incidence HIV− 18/100,000 inhabitants
Pulmonary tuberculosis annual incidence (total numbers) 1398
COPD admissions to hospital per year (number) 6383 [13, 15–17]
COPD admissions to hospital per year (prevalence) 71/100,000 adults
Asthma rate in adults 10% [13, 14]
Asthma numbers in adults 503,459
Cystic fibrosis total 320 [13, 18]
Cystic fibrosis adults 79
Table 4 Number of transplants in
2015 and estimated number of
cases of invasive aspergillosis
(IA)
Number Number of estimated
cases of IA
References
AML population frequency x/100,000 8.1 [3]
AML patients per year 852
Allogeneic HSCT per year 147 46 [3, 12]
Renal Tx per year 483 5 [3, 11]
Lung Tx per year 15 1
Heart Tx per year 50 3
Liver Tx per year 249 10
Lung cancer 3500 92
Total 4444 157
Eur J Clin Microbiol Infect Dis
Candida infection
Based on a one-year multicentre study conducted in 2010–
2011 involving ten district hospitals, the candidaemia rate
was found to be 2.19 per 100,000 inhabitants based on 240
episodes [34]. Despite the scarcity of systematic studies in our
country, the values found are more similar to the ones reported
in other countries in the north of Europe, such as Norway or
Finland (3–5 cases per 100,000 inhabitants). We, therefore,
anticipate a total of 231 cases of candidaemia per year. In a
multicentre study, 15 different Candida species were found,
with C. albicans (40%) being the most prevalent, followed by
C. parapsilosis (23%) and C. glabrata (13%) [34].
The cases of Candida peritonitis were estimated as the
proportion of candidaemia cases in the intensive care unit
(ICU), while there was one case of peritonitis per every two
cases of candidaemia and, therefore, 40 cases of post-surgical
Candida peritonitis were estimated to occur annually. The
sensitivity of Candida detection in blood cultures is about
40% [35], so invasive candidiasis is certainly under-
represented.
According to previous studies [36], the ratio of HIV pa-
tients without antiretroviral therapy and CD4 counts below
200 × 106/μL affected with oral candidiasis is 90%.
Therefore, we estimate a number of 2059 HIV patients with
oral candidiasis during 2014, assuming that half of the patients
without antiretroviral therapy presented CD4 counts below
200 × 106/μL. We have found neither official records nor
studies on the prevalence of oral candidiasis in patients with
cancer or after transplant nor the number of patients who are
denture wearers, as these are other conditions commonly as-
sociated with oral candidiasis. The same applies to people
living with diabetes mellitus. The number of oesophageal can-
didiasis in HIV patients was estimated assuming 20% of pa-
tients with HIV not on ARVs and with CD4 counts below 200
× 106/μL and 5% of those on ARVs (Table 2).
Recurrent vaginal thrush (rVVC) is defined as at least four
episodes every year. The self-reported rate of rVVC in five
European countries and the USAwas 9%, with some variation
between age groups. However, this is probably an over-esti-
mate, as it is based on self-diagnosis, so we have applied a 6%
rate. As many as 150,699 Portuguese women between 15 and
50 years of age get recurrent vaginal thrush every year. This
translates into an annual incidence of approximately 2854
cases per 100,000 females. The incidence of recurrent
Candida vaginitis is lower than our neighbour country [5]
but similar to other European studies [24, 25].
Dermatophyte infections
Regarding superficial mycoses, and using the global preva-
lence of 14.3% estimated by Vos et al. [37], 1,510,391
Portuguese inhabitants should have a skin fungal infection,
corresponding to an incidence of 14,300/1,000,000 inhabi-
tants, values similar to those obtained in other countries [5,
25].
In a study by Valdigem et al. [21], during the period 1983–
2002, 10,003 samples from the North of Portugal were
analysed and the frequency of dermatophytes was 23.6%,
with a prevalence of tinea capitis of 4.9%. A more recent
retrospective study, performed by the Portuguese National
Institute of Health [20], included 4193 biological samples
from patients within the NUTSII region of Lisbon and Tagus
Valley with medical suspicion of fungal infection, collected
from 2004 to 2013. The average frequency of dermatophyte
infection was 21%, ranging from 18 to 26%. Tinea capitis was
confirmed in 236 (28%) patients and was more frequent in
children from the age group 1–9 years old. In scalp
dermatomycosis, Microsporum audouinii was the most fre-
quently isolated species (n = 120, 51%), followed by
Trichophyton soudanense (n = 44, 19%). Onychomycosis
caused by dermatophytes was confirmed in 385 cases
(46%). Other fungi recognised as causes of onychomycosis
were not considered for this report. Skin samples were posi-
tive in 220 cases (26%). The most prevalent dermatophytes
isolated in nail and skin samples were T. rubrum (206 and 93
isolates, respectively) and T. mentagrophytes (49 and 39 iso-
lates respectively). Epidermophyton floccosum was the spe-
cies less frequently found in skin samples (1%). Our national
data shows a high prevalence of anthropophilic species
(M. audouinii and T. soudanense) in the region of Lisbon
and Tagus Valley, where the number of foreign citizens from
African countries is higher.
Other fungal infections
– Mucormycosis
In Spain, the estimated incidence was 0.43 cases/1 million
inhabitants [38], whereas this incidence in France was higher,
at 0.9 cases/1 million inhabitants [39]. Portugal has one of the
highest incidences of diabetes mellitus in Europe (13% of the
total population aged between 20 and 79 years old) [40]. We,
therefore, adopted the value of 0.9 cases/1 million inhabitants,
which translates into an annual incidence of ten cases. Among
the clinical reports published in Portugal between 2001 and
2015, 19 cases of mucormycosis were found.
– Histoplasmosis
Portugal receives many people from South America, espe-
cially from Brazil and also from Portuguese language African
countries. After the Independence of the African countries in
1974–1980, more than 1 million Portuguese people returned
to Portugal, and many of them are now over 60 years old.
Thus, we anticipate many individuals to have been exposed
to endemic fungi such as Histoplasma. Furthermore, Gascón
Eur J Clin Microbiol Infect Dis
et al. [41] estimates that the incidence of histoplasmosis is
20% for individuals who had travelled to Latin America for
the first time. According to the report of the Portuguese
Tourism Office in 2011, 2,458,900 Portuguese residents trav-
elled to the Americas and 1,154,000 travelled to Africa.
Bearing this in mind, we can estimate that 491,780
Portuguese travellers could have been infected by
H. capsulatum. However, our literature review found just ten
published cases of histoplasmosis between 2009 and 2015
(five var. capsulatum, five var. duboisii), with the majority
of them from Lisbon and Tagus Valley. Interestingly, some
of those cases refer manifestation of disease only after 40 years
after exposure [42]. According to the Diagnostic
Homogeneous Groups database [12], 16 episodes of histo-
plasmosis occurred in Portugal during 2014 (six in the North
Region, three in the centre and seven in Lisbon and Tagus
Valley).
– Paracoccidioidomycosis (PCM)
Paracoccidioidomycosis is an endemic systemic fungal in-
fection caused by the thermally dimorphic fungus
Paracoccidioides brasiliensis. Approximately 80% of PCM
cases in Latin America have been reported in Brazil. Since
Portugal has 165,530 Brazilian inhabitants [1], we believe that
this mycosis can be under-diagnosed in our country. Few case
reports diagnosed in Portugal are published.
Conclusion
This is a preliminary study but constitutes the first report of the
global burden of fungal infections in Portugal. Using pub-
lished and estimated data, we were able to estimate the inci-
dence or prevalence of the above referred fungal infections
and ∼1,695,514 (16%) people in Portugal suffer from those
fungal infections each year (Table 5). Skin and nail infections
were the most frequent fungal infection detected in this study,
followed by vaginal candidiasis. Additional studies are re-
qui red, especia l ly for d iseases such as al lerg ic
bronchopulmonary aspergillosis (ABPA) and severe asthma
with fungal sensitisation (SAFS).
Diagnosing infections remains a problem in the manage-
ment of fungal diseases, particularly in the immunocompro-
mised host. Signs and symptoms are non-specific, patients are
often unable to undergo invasive diagnostic procedures, colo-
nisation is difficult to distinguish from invasive disease and
blood cultures are commonly negative. Patients who have
thrombocytopaenia, severe bleeding disorders or other com-
plications cannot be subjected to biopsies. For this reason, the
autopsy is an important key to the understanding of the epide-
miology of invasive fungal infections, especially in the immu-
nocompromised host. The overall rates of autopsies decreasedTa
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in our country, which underscores the difficulty of obtaining
more precise data on the incidence and prevalence of invasive
fungal infections. Even bearing in mind the lack of sensitivity
of some methods, the available conventional diagnostic tools
in our country (cultural and serological methods) allow the
diagnosis of the most frequent fungal diseases. The implemen-
tation of molecular methods is also ongoing and is being cur-
rently done by specific Portuguese labs either for panfungal
DNA detection or to genus/species targeted detection. Since
Aspergillus resistance to azoles is becoming an emergent pub-
lic health concern in Europe, a new multiplex real-time poly-
merase chain reaction (PCR) assay that differentiates suscep-
tible from resistant A. fumigatus strains directly in clinical
samples is also available.
With the increase of individuals at risk for fungal infection
and the change in fungal epidemiology, clinicians and micro-
biologists must develop more expertise in the epidemiology,
pathogenicity and diagnostic methods of fungal infections in
order to address these challenges more adequately.
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